| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/DMRR.1114 |
| P953 | full work available at URL | https://orbi.uliege.be/bitstream/2268/80697/1/Efficacy%20and%20safety%20of%20saxagliptin%20in%20combinationOCR.pdf |
| https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fdmrr.1114 | ||
| https://onlinelibrary.wiley.com/doi/pdf/10.1002/dmrr.1114 | ||
| P698 | PubMed publication ID | 20824678 |
| P5875 | ResearchGate publication ID | 46171382 |
| P2093 | author name string | Guillaume Charpentier | |
| Asa Hellqvist | |||
| Carl Johan Ostgren | |||
| Ingrid Gause-Nilsson | |||
| André J. Scheen | |||
| P2860 | cites work | Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes | Q24642503 |
| Saxagliptin | Q28259979 | ||
| Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes | Q28262769 | ||
| Use and abuse of HOMA modeling | Q28263292 | ||
| The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone | Q34608300 | ||
| Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial | Q34610019 | ||
| Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone | Q34613240 | ||
| Current management strategies for coexisting diabetes mellitus and obesity | Q35147057 | ||
| New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond | Q37069916 | ||
| Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes | Q37175147 | ||
| Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control | Q37621774 | ||
| Addition of incretin therapy to metformin in type 2 diabetes | Q43086326 | ||
| Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18). | Q43225402 | ||
| Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17). | Q43245610 | ||
| Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes | Q43299560 | ||
| Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone. | Q45926533 | ||
| Earlier triple therapy with pioglitazone in patients with type 2 diabetes. | Q45926541 | ||
| Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. | Q45974567 | ||
| Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. | Q45974572 | ||
| Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy | Q46173840 | ||
| Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes | Q46804059 | ||
| Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. | Q51471806 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. | Q51478110 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. | Q51484788 | ||
| Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes | Q94681234 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| metformin | Q19484 | ||
| P304 | page(s) | 540-549 | |
| P577 | publication date | 2010-10-01 | |
| P1433 | published in | Diabetes - Metabolism: Research and Reviews | Q15750056 |
| P1476 | title | Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus | |
| P478 | volume | 26 |
| Q36730226 | A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus |
| Q44310507 | A patient-centred approach to treatment with incretin-based agents in patients with type 2 diabetes |
| Q35102138 | A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy |
| Q38266290 | A review of gliptins for 2014. |
| Q37965612 | A review of gliptins in 2011. |
| Q38067491 | A review of the efficacy and safety of oral antidiabetic drugs |
| Q37980541 | Alogliptin benzoate for the treatment of type 2 diabetes |
| Q37568863 | Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials |
| Q38163894 | Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors : meta-regression analysis of 78 randomized controlled trials with 20,053 patients. |
| Q59487668 | Bioequivalence of Saxagliptin/Metformin Extended-Release (XR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin XR Tablets in Healthy Adult Chinese Subjects |
| Q37427298 | Blood Glucagon Levels Predict the Hemoglobin A1c Response to Saxagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin |
| Q38113092 | Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes |
| Q38072259 | Cardiovascular effects of gliptins |
| Q43647206 | Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study |
| Q37949599 | Choosing a gliptin |
| Q37825941 | Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin |
| Q35717211 | Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease |
| Q26752468 | Clinically and pharmacologically relevant interactions of antidiabetic drugs |
| Q38057019 | Combination of glibenclamide-metformin HCl for the treatment of type 2 diabetes mellitus |
| Q37737474 | Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis |
| Q38017726 | Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors |
| Q33785197 | Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison |
| Q28546797 | Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis |
| Q38644587 | Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. |
| Q53181822 | Developing imprinted polymer nanoparticles for the selective separation of antidiabetic drugs. |
| Q37995760 | Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes |
| Q41863397 | Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus |
| Q99418678 | Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus |
| Q37468406 | Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin |
| Q58829034 | Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials |
| Q38126945 | Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety |
| Q38119146 | Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach |
| Q37195882 | Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin. |
| Q38018110 | Drug-induced hypoglycaemia in type 2 diabetes |
| Q91954110 | Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: A 12-Week Interim Report |
| Q33626226 | Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension |
| Q38100678 | Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin |
| Q51365356 | Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial. |
| Q55262447 | Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis. |
| Q51346295 | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. |
| Q34347884 | Emerging gliptins for type 2 diabetes |
| Q38219482 | Evidence-based practice use of incretin-based therapy in the natural history of diabetes |
| Q38074336 | Evolving therapeutic options for type 2 diabetes mellitus: an overview |
| Q37900151 | From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy |
| Q92062268 | GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials |
| Q38033468 | Glucagon-like peptide-1 and its cardiovascular effects |
| Q34265490 | Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis |
| Q38899869 | Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis. |
| Q38264374 | Implications of incretin-based therapies on cardiovascular disease. |
| Q38069507 | Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction |
| Q37837059 | Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience. |
| Q42633492 | Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials |
| Q51367101 | Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. |
| Q38004088 | Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis |
| Q38214060 | Management of unmet needs in type 2 diabetes mellitus: the role of incretin agents |
| Q37965618 | Metformin + saxagliptin for type 2 diabetes |
| Q35146648 | Observational and clinical trial findings on the comparative effectiveness of diabetes drugs showed agreement |
| Q86573766 | Once-weekly DPP-4 inhibitors: do they meet an unmet need? |
| Q38024861 | Overview of metformin: special focus on metformin extended release |
| Q34783302 | Overview of saxagliptin efficacy and safety in patients with type 2 diabetes and cardiovascular disease or risk factors for cardiovascular disease |
| Q35115112 | Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes |
| Q38470357 | Pharmacokinetic study of saxagliptin in healthy Chinese subjects |
| Q38734181 | Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes |
| Q38350347 | Pharmacologic treatment of type 2 diabetes: oral medications |
| Q30249371 | Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus |
| Q37910902 | Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. |
| Q27027877 | Safety and efficacy of sitagliptin-metformin in fixed combination for the treatment of type 2 diabetes mellitus |
| Q33412360 | Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus |
| Q34078449 | Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis |
| Q37963451 | Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies |
| Q38592351 | Saxagliptin: A Review in Type 2 Diabetes |
| Q35411329 | Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus |
| Q37973413 | Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU. |
| Q37870930 | Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials |
| Q36680066 | Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats |
| Q36523423 | Sitagliptin/Metformin (janumet) as combination therapy in the treatment of type-2 diabetes mellitus |
| Q39081543 | Sitagliptin: A Review in Type 2 Diabetes |
| Q37886184 | Sitagliptin: a review |
| Q38177173 | Sitagliptin: a review of its use in patients with type 2 diabetes mellitus |
| Q93382438 | Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes |
| Q38527885 | The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class? |
| Q92316034 | The Role of DPP-4 Inhibitors in the Treatment Algorithm of Type 2 Diabetes Mellitus: When to Select, What to Expect |
| Q42371758 | The Use of Saxagliptin in People with Type 2 Diabetes in France: The Diapazon Epidemiological Study |
| Q37992253 | The design of the liraglutide clinical trial programme |
| Q38205588 | The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]. |
| Q51365002 | The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors. |
| Q38088195 | The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists |
| Q27021870 | Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors |
| Q38006504 | Update on incretin hormones |
| Q38189114 | Vildagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of type 2 diabetes |
Search more.